News
Explanation proposed for long-COVID symptoms in the CNS
In the case of persistent neurologic symptoms after COVID, antibodies produced for previously encountered coronaviruses rather than for SARS-CoV2...
News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
News
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
News
LAA closure device shown safe in groups omitted in trials
New independent studies support safety of left atrial appendage closure devices in broad array of patient types.
News
Novel therapy shows promise for treating skin-predominant dermatomyositis
The study drug “is a potent, selective humanized IgG1-neutralizing antibody directed at IFN-beta,” said Dr. Aaron Mangold, the principal...
News
Studies validate IL-17 as hidradenitis suppurativa drug target
This clearly validates this target for the control of HS," reported lead investigator Alexa B. Kimball, MD, MPH.
News
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
News
Wearable fluid sensor lowers risk of HF rehospitalizations: BMAD
By detecting elevated thoracic fluid levels, a wearable device improves management and outcomes of heart failure.
News
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.
News
Fixed-dose combo pill for PAH promises accelerated benefit: A DUE
For pulmonary arterial hypertension, a fixed-dose combination of macitentan and tadalafil is safe and effective.
News
In early days, bioabsorbable stent rivals nonabsorbable devices
Late lumen loss with a new bioabsorbable drug-eluting stent is on par with nonabsorbable devices in early data.
News
Long-term BP reductions with renal denervation not race specific
Long-term blood pressure reductions in the Black patient cohort of the SYMPLICITY renal denervation trial challenge early results.
News
Causal AI quantifies CV risk, providing patient-specific goals
Causal artificial intelligence is showing how specific risk factors can be overcome to avoid cardiovascular events.
News
When intravascular imaging guides complex PCI, MACE risk is lowered
In stent placement for complex coronary lesions, intravascular imaging reduces events relative to angiography.